VRTX - These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q3 Results | Benzinga
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported upbeat earnings for its third quarter, while sales missed estimates.
Vertex Pharmaceuticals posted adjusted earnings of $4.08 per share, beating market estimates of $3.98 per share. The company’s quarterly sales came in at $2.48 billion versus expectations of $2.50 billion.
Vertex said it now sees FY23 sales of around $9.85 billion from its CF treatments.
Vertex shares fell 0.6% to trade at $383.51 on Tuesday.
These analysts made changes to their price targets on Vertex Pharmaceuticals following earnings announcement.
- HC ...